Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
60
Views
3
CrossRef citations to date
0
Altmetric
Case Report

EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report

Zhiqin Lu1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9159-9562
ORCID Icon,
Xia Wang1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China;2 Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6986-0979
ORCID Icon,
Yuxi Luo1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China
,
Jianping Wei1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China
,
Zhimin Zeng1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China;2 Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0959-3044
ORCID Icon,
Qiang Xiong1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China;2 Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi Province, People’s Republic of China
,
Jing Cai1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China;2 Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi Province, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Anwen Liu1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China;2 Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi Province, People’s Republic of China
 show all
Pages 2823-2828 | Published online: 23 Apr 2021

References

  • Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43–e55. doi:10.1016/S1470-2045(17)30689-7
  • Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol. 2016;11(11):1962–1969. doi:10.1016/j.jtho.2016.06.029
  • Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371–2376. doi:10.1093/annonc/mdt205
  • Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281. doi:10.1158/1078-0432.CCR-13-0318
  • Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242(3):882–888. doi:10.1148/radiol.2423051707
  • Shin HJ, Kho BG, Kim MS, et al. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: case series. Medicine. 2019;98(9):e14699. doi:10.1097/MD.0000000000014699
  • Zhao Y, Wang S, Zhang B, et al. Clinical management of non-small cell lung cancer with concomitant EGFR mutations and ALK rearrangements: efficacy of EGFR tyrosine kinase inhibitors and crizotinib. Target Oncol. 2019;14(2):169–178. doi:10.1007/s11523-019-00628-6
  • Wang X, Zhong D. Advances in double mutations of EGFR and ALK gene in non-small cell lung cancer. Chin J Lung Cancer. 2018;21(9):686–691. doi:10.3779/j.issn.1009-3419.2018.09.07
  • Wecker H, Waller CF. Afatinib. Recent Results Cancer Res. 2018;211:199–215. doi:10.1007/978-3-319-91442-8_14
  • Tamiya A, Tamiya M, Nishihara T, et al. Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a Multicenter Prospective Study. Anticancer Res. 2017;37(8):4177–4182. doi:10.21873/anticanres.11806
  • Ma C, Wang S, Mu N, et al. Effective treatment with afatinib of lung adenocarcinoma with leptomeningeal metastasis harboring the Exon 18 p.G719A mutation in the EGFR gene was detected in cerebrospinal fluid: a case report. Front Oncol. 2020;10:1635. doi:10.3389/fonc.2020.01635
  • Lee J, La Choi Y, Han J, et al. Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status. J Thorac Oncol. 2020;15(11):1758–1766. doi:10.1016/j.jtho.2020.06.018
  • Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838. doi:10.1016/S1470-2045(15)00026-1
  • Zhang SR, Zhu LC, Jiang YP, et al. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin. 2017;38(2):233–240. doi:10.1038/aps.2016.107
  • Brueckl WM, Laack E, Reck M. Efficacy of afatinib in the clinical practice: first results of the GIDEONtrial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany. Ann Oncol. 2018;29:viii524. doi:10.1093/annonc/mdy292.071
  • Yang JJ, Zhang XC, Su J, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014;20(5):1383–1392. doi:10.1158/1078-0432.CCR-13-0699
  • Won JK, Keam B, Koh J, et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol. 2015;26(2):348–354. doi:10.1093/annonc/mdu530
  • Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–4283. doi:10.1158/1078-0432.CCR-08-0168
  • Schmid S, Gautschi O, Rothschild S, et al. Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol. 2017;12(4):681–688. doi:10.1016/j.jtho.2016.12.003

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.